【摘要】 炎症性肠病（inflammatory bowel disease,IBD）是一种以胃肠道慢性炎症为特征的复杂疾病，其临床治疗面临诸多挑战。尽管当前药物治疗方案在缓解临床症状方面展现出一定疗效，但长期应用仍存在感染等治疗相关风险，凸显出对新型治疗策略的迫切需求。近年来，间充质干细胞（mesenchymal stem cells,MSCs）衍生细胞外囊泡（extracellular vesicles,EVs）因其在免疫调节领域的独特优势，逐渐成为IBD治疗的研究新热点，有望成为IBD治疗领域的一种创新且有效的治疗策略。本文综述了EVs在IBD治疗领域中的最新进展，主要包括EVs的质量控制标准、免疫调节机制以及工程化策略等内容。本综述旨在为MSC-EVs在IBD的临床转化治疗领域提供参考。同时，探讨了通过工程化手段增强MSC-EVs药效的新策略，为该领域的研究开辟了创新思路。更多还原

【Abstract】 Inflammatory bowel disease(IBD) is a complex disorder characterized by chronic inflammation in the gastrointestinal tract, posing numerous challenges in its clinical management. Although current pharmacological treatment regimens demonstrate certain efficacy in alleviating clinical symptoms, their long-term use is associated with treatment-related risks such as infections, highlighting the urgent need for novel therapeutic strategies. In recent years, extracellular vesicles(EVs) derived from mesenchymal stem cells(MSCs) have emerged as a novel research focus in the treatment of IBD due to their unique advantages in the field of immunoregulation, holding promise as an innovative and effective therapeutic strategy in this area.This article reviews the latest advancements in the use of EVs for IBD treatment, encompassing topics such as EV quality control standards, immunoregulatory mechanisms, and engineering strategies. The objective of this review is to provide guidance for the clinical translational application of MSC-EVs in IBD treatment. Additionally, it explores novel strategies to enhance the therapeutic efficacy of MSC-EVs through engineering approaches, opening up innovative avenues for research in this field.更多还原